Acute Coronary Syndrome – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1.Introduction

1.1. Report Overview

2. AcuteCoronary Syndrome - Overview

3. ExecutiveSummary

4. AcuteCoronary Syndrome : Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. AcuteCoronary Syndrome: Company & Drug Profiles

5.1. Clinical Stage

5.1.1. PICSO – Miracor Medical SA

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. P2Y12 inhibitor – Samsung Medical Center

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. VitalScan Magnetocardiograph – Creavo Medical Technologies Ltd

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. AcuteCoronary Syndrome: An Overview on Dormant & Discontinued PipelineCandidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. AcuteCoronary Syndrome: Additional Key Insights

7.1. Epidemiology Overview: Acute CoronarySyndrome

7.2. Current Market Scenario: AcuteCoronary Syndrome Therapeutics

8. Acute Coronary Syndrome: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.